ATS Corporation Q4 2026 Earnings Call Summary

1Key Financial Results and Metrics

Q4 Revenue: $744 million, up 3.2% year-over-year.

Adjusted Earnings from Operations: $76.8 million, a 3.4% increase from Q4 last year.

Gross Margin: 29.4%, a 36 basis point increase year-over-year.

Order Bookings: $704 million, down 18.4% compared to Q4 last year, reflecting prior large project awards.

Order Backlog: Approximately $2 billion, with Life Sciences comprising $1.1 billion (55% of total).

Adjusted EPS: $0.36 for the quarter.

Free Cash Flow: $149.5 million, marking six consecutive quarters of positive growth.

Net Debt to Adjusted EBITDA Ratio: 2.8x, showing continued improvement.

2Strategic Updates and Business Highlights

ATS is consolidating its transportation operations, moving away from large-scale automotive projects to focus on specialized applications.

The company is enhancing its digital twin offerings and integrating aftermarket services into operating units to improve margins and revenue predictability.

Strong performance in Life Sciences, particularly in the radiopharma sector, with a broader funnel of opportunities beyond single program types.

Energy sector backlog increased by approximately 40% year-over-year, driven by nuclear refurbishment and new build programs.

ATS is focused on capital efficiency and margin expansion, with plans for targeted investments in growth areas like nuclear and radiopharma.

3Forward Guidance and Outlook

Q1 2027 Revenue Guidance: Expected to be in the range of $700 million to $740 million.

Fiscal 2027 Outlook: Modest revenue growth anticipated, with the transportation segment expected to decline.

Margin Improvement: Expected adjusted earnings from operations margins to improve by 50 to 75 basis points over fiscal 2026, supported by reorganization actions and operational discipline.

Long-term margin target remains at 15%.

4Bad News, Challenges, or Points of Concern

Declining Order Bookings: The 18.4% drop in order bookings raises concerns about future revenue growth, particularly in the consumer products segment.

Transportation Segment: The decision to exit large-scale automotive work may lead to a revenue decline of approximately $50 million.

Market Volatility: The company noted potential lumpiness in revenue due to timing of large orders and market dynamics, particularly in Life Sciences.

Geopolitical and Trade Uncertainty: Ongoing macroeconomic challenges could impact future performance, although current tariffs have not materially affected operations.

5Notable Q&A Insights

Life Sciences Backlog: Management remains optimistic about growth in Life Sciences, despite some moderation in GLP-1 auto-injector orders. The focus will be on diversifying the backlog with radiopharma and other applications.

M&A Activity: ATS plans to pursue M&A opportunities independently of the ongoing restructuring, viewing both as capital deployment exercises.

Working Capital Management: Strong performance in working capital efficiency is a priority, with a target of maintaining levels below 15%.

Recurring Revenues: Approximately one-third of ATS's business is recurring, with initiatives underway to increase this percentage, which tends to be margin-accretive. Overall, ATS Corporation's Q4 2026 results reflect solid execution and strategic focus, but challenges in order bookings and market volatility present potential headwinds for the upcoming fiscal year.